The round was led by Transformation Capital with participation from Twelve Below, Virtue Ventures and others. The round brings total funding to approximately $25 million. The capital will fuel go-to-market expansion, accelerate product development and enable Solstice to grow its team across product and customer-facing functions. Few business challenges are as high-stakes and time-sensitive as commercializing a new drug or medical product.

Solstice is the AI-native marketing agency for pharma brands. The company pairs AI technology with in-house experts to generate, review and activate compliant marketing content at speed, replacing the traditional handoffs between agencies, regulatory teams and in-house marketers.